Jeff, I share your disappointment, but while it
Post# of 148169
(Total Views: 846)
Posted On: 11/03/2020 8:47:17 AM
Jeff,
I share your disappointment, but while it is painful that we are still reaching for sufficient enrollment, better to have clean data, unlike remdesivir with apparently not-blinded results and neurocrine applying for rlf EUA on open label results.
EINDs are a great indication of efficacy, not proof that the world needs. We cannot have the world pivoting to a cure until it is proven, whether that is leronlimab or another therapeutic.
I share your disappointment, but while it is painful that we are still reaching for sufficient enrollment, better to have clean data, unlike remdesivir with apparently not-blinded results and neurocrine applying for rlf EUA on open label results.
EINDs are a great indication of efficacy, not proof that the world needs. We cannot have the world pivoting to a cure until it is proven, whether that is leronlimab or another therapeutic.
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼